Therapeutic Type: Disease modification

Model Overview Various iterations of the MPTP-lesioned mouse are offered by Atuka. In our most commonly used model, MPTP (25 mg/kg, i.p.) is administered to C57bl/6 mice once daily for 5 days. This leads to a loss of tyrosine hydroxylase positive neurons in the substantia nigra that is stable over a period of weeks. Test…